An overview on the expression of cyclooxygenase-2 in tumors of the head and neck

Oral Oncology

Volumn 45, Issue 10, 2009, Pages

  Mendes, Rui Amaral ^a,b   Carvalho, João F C ^a   Waal, Isaac van der ^c  

^a U Porto   (Portugal)

^b UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Apoptosis; COX 2; Head and neck; Jaws; Moleculartargeted therapy; Oncogenes; Tumor

Indexed keywords

CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; MOLECULAR MARKER; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEIN P53; TRANSCRIPTION FACTOR AP 1;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CELL ADHESION; CELL PROLIFERATION; CONCENTRATION RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; JAW CANCER; METASTASIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; CYCLOOXYGENASE 2; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDINS;

EID: 70349105524     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.03.016     Document Type: Review

References (75)

1. Prescott S.M., and Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochem Biophys Acta 1470 (2000) 69-78
2. Shibata M., Kodani I., Osaki M., Araki K., Adachi H., Ryoke K., et al. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 41 (2005) 304-312
3. Mohan S., and Epstein J.B. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 39 (2003) 537-546
4. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 (1999) 991-994
5. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., and Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33 (2002) 708-714
6. Buchanan F.G., Wang D., Bargiacchi F., and DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 (2003) 35451-35457
7. 2 in human head and neck xenograft tumors. Cancer Res 62 (2002) 6706-6711
8. Kutchera W., Jones D.A., Matsunami N., Groden J., McIntyre T.M., Zimmerman G.A., White R.L., et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence of transcriptional effect. Proc Natl Acd Sci USA 93 (1996) 4816-4820
9. Eberhart C.E., Coffey R.J., Radhika F.M., Giardello S., Ferenbach S., and DuBois R.N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1996) 1183-1188
10. Hida T., Yatabe Y., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58 (1998) 3761-3764
11. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276 (2001) 18563-18569
12. Lin D.T., Subbaramaiah K., Shah J.P., Dannenberg A.J., and Boyle J.O. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24 (2002) 792-799
13. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med 8 (2002) 289-293
14. Jackel E.C., Raja S., Tan J., Das S.K., Dey S.K., Griod D.A., et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, peroxisome proliferator-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 1253-1259
15. Gupta R.A., and DuBois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev Cancer 1 (2001) 11-21
16. Nishimura G., Yanoma S., Mizuno H., Kawakami K., and Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Japan J Cancer Res 90 (1999) 1152-1162
17. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck cancer. Cancer Res 59 (1999) 991-994
18. Smith W.L., Dewitt D.L., and Garavito R.M. Cyclooxygenase: structural, cellular and molecular biology. Ann Rev Biochem 69 (2000) 145-182
19. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cycloxygenases)-1&2. J Biol Chem 271 (1996) 33157-33160
20. Waddell W.R., and Miesfeld R.L. Adenomatous polyposis coli, protein kinase, protein tyrosine phosphate. J Surg Oncol 58 (1995) 252-256
21. Renkonen J., Wolff H., and Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 440 (2002) 594-597
22. Lee D.W., Sung M.W., Park S.W., Seong W.J., Roh J.L., Park B., et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of head and neck: Inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 22 (2002) 2089-2096
23. Nathan C.A., Leskov I.L., Lin M., et al. COX-2 expression in dysplasia of the head and neck: correlation with elf4E. Cancer 92 (2001) 1888-1895
24. Loro L.L., Johannessen A.C., and Vintermyr O.K. Decreased expression of bcl-2 in moderate and severe oral epithelial dysplasias. Oral Oncol 38 (2002) 691-698
25. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., and Sampat A. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274 (1999) 10911-10915
26. Mestre J.R., Subbaramaiah K., Sacks P.G., Stimson P., Schantz S.P., Tanabe T., et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 57 (1997) 2890-2895
27. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor-(alpha) and epidermal growth factor messenger mRNA as early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (1993) 3579-3584
28. Shin D.M., Ro J.Y., Hong W.K., and Hittleman W.N. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54 (1994) 3153-3159
29. Sumitani K., Kamijo R., Toyoshima T., Nakanishi Y., Takizawa K., Hatori M., et al. Specific inhibition of cycloooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30 (2001) 441-447
30. Subbaramaiah K., Michaluart P.K., Sporn M.B., and Dannenberg A.J. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res 60 (2000) 2399-2404
31. Tsujii M., and DuBois R.N. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell 83 (1995) 493-501
32. Williams C.S., Tsujii M., Reese J., Dey S.K., and DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105 (2000) 1589-1594
33. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 5 (1996) 803-809
34. Suyama Y., Kubota Y., Ninomiya T., and Shirasuna K. Immunohistochemical analysis of interleukin-1 alpha, its type I receptor and antagonist in keratocystic odontogenic tumors. J Oral Pathol Med 37 (2008) 560-564
35. Ogata S., Kubota Y., Yamashiro T., Takeuchi H., Ninomiya T., Suyama Y., et al. Signaling pathways regulating IL-1alpha-induced COX-2 expression. J Dent Res 86 (2007) 186-191
36. Sheng H., Shao J., Marrow J.D., Beauchamp R.D., and DuBois R.N. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 (1998) 362-366
37. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori H., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
38. Mifflin R.C., Saada J.I., Mari J.F., Adegboyega P.A., Valentich J.D., and Powell D.W. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol 282 (2002) 824-834
39. 2-mediated bone resorption associated with inflammation. J Exp Med 197 (2003) 1303-1310
40. Yang C.M., Chien C.S., Hsiao L.D., Luo S.F., and Wang C.C. Interleukin-1beta-induced cyclooxygenase-2 expression is mediated through activation of p42/44 and p38 MAPKS, and NFkappaB pathways in canine tracheal smooth muscle cells. Cell Signal 14 (2002) 899-911
41. Oka S., Kubota Y., Yamashiro T., Ogata S., Ninomiya T., Ito S., et al. Effects of positive pressure in odontogenic keratocysts. J Dent Res 84 (2005) 913-918
42. Catley M.C., Chivers J.E., Cambridge L.M., Holden N., Slater D.M., Staples K.J., et al. IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett 547 (2003) 75-79
43. Di Mari J.F., Mifflin R.C., Adegboyega P.A., Saada J.I., and Powell D.W. IL-1alpha-induced COX-2 expression in human intestinal myofibroblasts is dependent on a PKCzeta-ROS pathway. Gastroenterology 124 (2003) 1855-1865
44. Molina-Holgado E., Ortiz S., Molina-Holgada F., and Guaza C. Induction of COX-2 and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Brit J Pharmacol 131 (2000) 152-159
45. Lin C.H., Sheu S.Y., Lee H.M., Ho Y.S., Lee W.S., Ko W.C., et al. Involvement of protein kinase C-gamma in IL-1beta-induced cyclooxygenase-2 expression in human pulmonary epithelial cells. Mol Pharmacol 57 (2000) 36-43
46. 2. Biochem Biophys Res Commun 137 (1986) 404-410
47. 2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154 (1995) 3383-3390
48. Stolina M., Sharma S., Lin Y., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164 (2000) 361-370
49. Corcoran C.A., He Q., Huang Y., and Sheikh M.S. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 24 (2005) 1634-1640
50. Atula T., Hedström J., Ristimäki A., Finne P., Leivo I., Markkanen-Leppänen M., et al. Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. Oncol Rep 16 (2006) 485-490
51. Gallo O., Schiavone N., Papucci L., Sardi I., Magnelli L., Franchi A., et al. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol 163 (2003) 723-732
52. Leung W.K., To K.F., Ng Y.P., Lee T.L., Lau J.Y., Chan F.K., et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Brit J Cancer 84 (2001) 335-339
53. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62 (2002) 632-635
54. Erkinheimo T.L., Lassus H., Finne P., van Rees B.P., Leminen A., Ylikorkala O., et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 10 (2004) 538-545
55. Nylander K., Nilsson P., Mehle C., and Roos G. P53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Brit J Cancer 71 (1995) 826-830
56. Sjogren S., Inganas M., Norberd T., Lindgren A., and Nordgren H. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88 (1996) 173-182
57. Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2. Proliferation and genetic studies. Oral Oncol 38 (2002) 323-331
58. Subbaramaiah K., Norton L., Gerald W., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 277 (2002) 18649-18657
59. Kolár Z., Geierová M., Bouchal J., Pazdera J., Zboril V., and Tvrdý P. Immunohistochemical analysis of the biological potential of odontogenic keratocysts. J Oral Pathol Med 35 (2006) 75-80
60. 2+ stimulates COX-2 expression through calcium-sensing receptor in fibroblasts. Biochem Biophys Res Commun 351 (2006) 808-814
61. Kichi E., Enokiya Y., Muramatsu T., Hashimoto S., Inoue T., Abiko Y., et al. Cell proliferation, apoptosis and apoptosis-related factors in odontogenic keratocysts and in dentigerous cysts. J Oral Pathol Med 34 (2005) 280-286
62. Lu Q.L., Abel P., Foster C.S., and Lalani E.N. Bcl-2: role in epithelial differentiation and oncogenesis. Human Pathol 27 (1996) 102-110
63. Chylicki K., Ehinger M., Svedberg H., and Gullberg U. Characterization of the molecular mechanisms for p53-mediated differentiation. Cell Growth Differ 11 (2000) 561-571
64. Joensuu H., Pylkkanen L., and Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145 (1994) 1191-1198
65. Hellemans P., Van Dam P.A., Weyler J., Van Oosterom A.T., Buytaert P., and Vav Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Brit J Cancer 72 (1995) 354-360
66. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83 (1995) 493-501
67. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
68. Gallo O., Franchi A., Magnelli L., et al. Cyclo-oxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3 (2001) 53-61
69. Kumamoto H., Ohki K., and Ooya K. Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. J Oral Pathol Med 31 (2002) 28-34
70. Kumamoto H. Molecular pathology of odontogenic tumors. J Oral Pathol Med 35 (2006) 65-74
71. Dohadwala M., Luo J., Zhu L., et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276 (2001) 20809-20812
72. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci 94 (1997) 3336-3340
73. Bergmann C., Strauss L., Zeidler R., Lang S., and Whiteside T.L. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67 (2007) 8865-8873
74. Choe M.S., Zhang X., Shin H.J., Shin D.M., and Chen Z.G. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4 (2005) 1448-1455
75. Chen Z., Zhang X., Li M., Wang Z., Wieand H.S., Grandis J.R., et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10 (2004) 5930-5939